Literature DB >> 14614884

Epidemiology of gestational trophoblastic diseases.

Stephen James Steigrad1.   

Abstract

The epidemiology of gestational trophoblastic diseases is unclear. Problems with collection and interpretation of differing data abound. Hydatidiform mole (HM) is associated with abnormal gametogenesis and/or fertilization. This is further influenced by age, ethnicity and a prior history of an HM suggesting a genetic basis for its aetiology. Whilst a prior HM is significant in the development of trophoblastic neoplasia there is no clear explanation for the development of gestational trophoblastic neoplasia in association with a normal gestation. The development and improvements in suction curettage, termination of pregnancy, contraceptive techniques, diagnostic imaging and biochemical testing have been associated not only with a fall in the birth rate, but also with a reduction in the incidence of trophoblastic diseases. Future study should examine the mechanism of malignant change in normal and abnormal trophoblast.

Entities:  

Mesh:

Year:  2003        PMID: 14614884     DOI: 10.1016/s1521-6934(03)00049-x

Source DB:  PubMed          Journal:  Best Pract Res Clin Obstet Gynaecol        ISSN: 1521-6934            Impact factor:   5.237


  32 in total

Review 1.  The hydatidiform mole.

Authors:  Jean-Jacques Candelier
Journal:  Cell Adh Migr       Date:  2015-09-30       Impact factor: 3.405

2.  Genome-wide definitive haplotypes determined using a collection of complete hydatidiform moles.

Authors:  Yoji Kukita; Katsuyuki Miyatake; Renee Stokowski; David Hinds; Koichiro Higasa; Norio Wake; Toshio Hirakawa; Hidenori Kato; Takao Matsuda; Krishna Pant; David Cox; Tomoko Tahira; Kenshi Hayashi
Journal:  Genome Res       Date:  2005-11       Impact factor: 9.043

3.  Differential expression of E-cadherin, β-catenin, and Lewis x between invasive hydatidiform moles and post-molar choriocarcinomas.

Authors:  Jean-Jacques Candelier; Lucien Frappart; Ange Lucien Diatta; Tarik Yadaden; Mamadou-Lamine Cissé; Jean-Marie Afoutou; Jean-Yves Picard; Benoît Mennesson; Rima Slim; Karim Si-Tayeb; Philippe Coullin
Journal:  Virchows Arch       Date:  2013-05-17       Impact factor: 4.064

4.  Hydatidiform moles among patients with incomplete abortion in Mwanza City, North western Tanzania.

Authors:  Bernard Kitange; Dismas Matovelo; Eveline Konje; Anthony Massinde; Peter Rambau
Journal:  Afr Health Sci       Date:  2015-12       Impact factor: 0.927

Review 5.  Gestational trophoblastic neoplasia: the management of relapsing patients and other recent advances.

Authors:  Naveed Sarwar; Edward S Newlands; Michael J Seckl
Journal:  Curr Oncol Rep       Date:  2004-11       Impact factor: 5.075

6.  Altered p16 and Bcl-2 expression reflects pathologic development in hydatidiform moles and choriocarcinoma.

Authors:  Jean-Jacques Candelier; Lucien Frappart; Tarik Yadaden; Henriette Poaty; Jean-Yves Picard; Sophie Prévot; Philippe Coullin
Journal:  Pathol Oncol Res       Date:  2012-10-13       Impact factor: 3.201

Review 7.  Prophylactic chemotherapy for hydatidiform mole to prevent gestational trophoblastic neoplasia.

Authors:  Qiuyi Wang; Jing Fu; Lina Hu; Fang Fang; Lingxia Xie; Hengxi Chen; Fan He; Taixiang Wu; Theresa A Lawrie
Journal:  Cochrane Database Syst Rev       Date:  2017-09-11

8.  Angiogenic dysfunction in molar pregnancy.

Authors:  David Kanter; Marshall D Lindheimer; Eileen Wang; Romana G Borromeo; Elizabeth Bousfield; S Ananth Karumanchi; Isaac E Stillman
Journal:  Am J Obstet Gynecol       Date:  2010-02       Impact factor: 8.661

9.  Relationship of Histopathological Representation of Excessive Proliferation of Trophoblast Cells with the Possibility of Malignant Events After Complete Hydatidiform Mole.

Authors:  Maringan Tobing; Futiha Arabia; Yudi Hidayat; Kemala Mantilidewi
Journal:  Int J Gen Med       Date:  2021-05-18

10.  Bioinformatics Analysis of Choriocarcinoma-Related MicroRNA-Transcription Factor-Target Gene Regulatory Networks and Validation of Key miRNAs.

Authors:  Xiaotong Peng; Zhirong Zhang; Yanqun Mo; Junliang Liu; Shuo Wang; Huining Liu
Journal:  Onco Targets Ther       Date:  2021-06-29       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.